News
Long-term results from the clinical study with UV1 in combination with ipilimumab in patients with malignant melanoma presented at the 2020 ASCO-SITC conferance.
Technology
Ultimovacs is developing a universal cancer vaccine applicable across a broad spectrum of cancer types.
Clinical studies
Lead product tested in three clinical trials, strong results justifies the initiation of a registration trial.